Summary of Conference Call for Yuan Dong Bio (苑东生物) Company Overview - **Company**: Yuan Dong Bio (苑东生物) - **Industry**: Pharmaceutical, focusing on drug development and research Key Points R&D Performance and Future Outlook - Yuan Dong invests 20% of its revenue annually in R&D, ranking among the top in the A-share market [3] - The company is transitioning from high-end generic drugs to more competitive controlled narcotics, achieving significant results [3] - Two Class II controlled narcotics, Nabuphine and Butorphanol, are expected to be approved in 2024, with sales projected to grow from 60 million RMB in 2025 to over 200 million RMB by 2026 [3][4] - The company faces challenges in the non-controlled antagonist product segment due to centralized procurement impacts, and its efficiency in developing new Class I drugs is lagging behind competitors [3][5] Strategic Developments - The Shanghai Chaoyang platform enhances the company's capabilities in developing Class I new drugs, particularly the IKZF13 molecular glue for multiple myeloma, which has a significant market potential [6][7] - HP001, a new drug in clinical trials, shows promising results with an objective response rate (ORR) of 83.3% in high-dose groups, outperforming some combination therapies [10] Competitive Landscape - The company is monitoring competition from BeiGene and Nurix in the BTK ProTech product space, with HP002 aiming to replicate BeiGene's success [11] - VAVONE molecular glue HP003 is being developed to target autoimmune oral therapies, showing better efficacy than existing products [12] Future R&D Directions - The company plans to extend its R&D focus to the Dac platform, utilizing molecular glue as a payload, with promising preliminary data [13] - Key developments expected by 2026 include significant data from VIV1 molecular glue, BDK protect IND, and IKZF13 molecules [13] Financial Projections - The overall valuation of the company is projected to reach 25.5 billion RMB by 2026, with the main business valued at approximately 8 billion RMB [14] - Anticipated profits for 2025 are estimated between 270 million to 280 million RMB, with a growth rate of over 20% expected to continue [14][15] Additional Insights - The company has faced challenges in the past few years, particularly in the Class I new drug sector, with only one drug entering Phase I clinical trials in the last decade [5] - The focus on improving R&D efficiency and quality is expected to positively influence future operational trends [15]

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected performance that exceeds the market by more than 5% over the next six months [29]. Core Insights - The report highlights that the national government will continue to support the renewal of medical equipment in 2026, which is expected to drive demand in the medical device sector. The focus is on high-end equipment and companies with significant performance improvements and international expansion, such as Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical [3]. - The report emphasizes the optimization of application conditions and review processes for equipment renewal projects, aiming to lower investment thresholds and enhance support for small and medium-sized enterprises [3]. - The ongoing policy for equipment renewal is anticipated to sustain a favorable bidding environment for medical devices, with a gradual improvement in performance as inventory clears [3]. Summary by Sections Industry Overview - The report discusses the government's announcement on December 30, 2025, regarding large-scale equipment renewal and the inclusion of various sectors, including healthcare, in the support framework for 2026 [3]. - It outlines the measures to improve the application process for equipment renewal, including stricter requirements for equipment depreciation and minimum usage periods [3]. Investment Opportunities - The report suggests focusing on companies that are expected to show significant performance improvements and have a leading international presence in the medical device sector [3]. - Specific companies recommended for investment include Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical, which are well-positioned to benefit from the anticipated demand for high-end medical equipment [3]. Market Performance - The medical sector has experienced a decline, with a reported drop of 2.06% in the last week, ranking 25th among 28 industries [8][18]. - The report notes that the medical device market is under pressure in the short term due to policy impacts, but improvements are expected as companies innovate and expand internationally [5].

Market Overview - On December 30, A-shares experienced a narrow range consolidation with quick sector rotation, closing with the Shanghai Composite Index slightly down at 3965.12 points, while the Shenzhen Component Index rose by 0.49% and the ChiNext Index increased by 0.63%. The total trading volume for A-shares was 2.16 trillion yuan [1]. Capital Flow - The net outflow of main funds in the Shanghai and Shenzhen markets exceeded 23 billion yuan, with an opening net outflow of 11.62 billion yuan and a closing net outflow of 4.02 billion yuan, resulting in a total net outflow of 23.83 billion yuan for the day [2][3]. - The CSI 300 index saw a net inflow of 0.375 billion yuan, while the ChiNext experienced a net outflow of 7.857 billion yuan [4]. Sector Performance - The following sectors had significant net inflows: - Non-ferrous metals: 8.432 billion yuan, with notable inflow into Yun Aluminum [6]. - Automotive: 3.940 billion yuan, with significant inflow into Shanzigaoke [6]. - Electronics: 3.763 billion yuan, with notable inflow into Shuo Beid [6]. - Machinery: 3.049 billion yuan, with significant inflow into Juyi Suoj [6]. - Oil and petrochemicals: 1.625 billion yuan, with notable inflow into Hengyi Petrochemical [6]. - The sectors with the largest net outflows included: - Utilities: -5.219 billion yuan, with significant outflow from Mindong Electric Power [6]. - Computers: -5.215 billion yuan, with notable outflow from Tuo Wei Information [6]. - Defense and military: -5.048 billion yuan, with significant outflow from Aerospace Development [6]. - Electric power equipment: -4.647 billion yuan, with notable outflow from Goldwind Technology [6]. - Retail: -4.425 billion yuan, with significant outflow from Gongxiao Daji [6]. Institutional Activity - The top stocks with net institutional purchases included: - Tailor Co., Ltd.: 152.31 million yuan, with a daily increase of 9.97% [8]. - Aerospace Development: 134.72 million yuan, with a daily decrease of 3.13% [8]. - Longi Machinery: 77.13 million yuan, with a daily increase of 5.78% [8]. - The stocks with the largest net institutional sales included: - Zhejiang Shibao: -615.44 million yuan, with a daily decrease of 10.01% [10]. - Electric Media: -738.89 million yuan, with a daily decrease of 10.00% [10]. Institutional Focus - Recent institutional ratings and target prices for selected stocks include: - Liu Gong: Strong Buy with a target price of 16.50 yuan, current price 11.95 yuan, indicating a potential upside of 38.08% [11]. - Stone Technology: Strong Buy with a target price of 224.10 yuan, current price 151.81 yuan, indicating a potential upside of 47.62% [11]. - Chip Source Micro: Buy with a target price of 167.18 yuan, current price 144.99 yuan, indicating a potential upside of 15.30% [11].

Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of 87.6 CNY per share [2][10]. Core Insights - The report emphasizes the company's differentiated innovation capabilities, particularly through the integration of its research and development (R&D) systems, which is expected to enhance its competitive edge in the pharmaceutical market [8][9]. - The company has made significant strides in its product pipeline, particularly in the controlled narcotics sector, and is poised to become a leader in this field [26][27]. - The integration of Shanghai Chaoyang, focusing on targeted protein degradation, is expected to bolster the company's R&D capabilities and expand its product offerings [9][10]. Financial Summary - Total revenue projections for 2024A, 2025E, 2026E, and 2027E are 1,350 million, 1,376 million, 1,567 million, and 1,933 million CNY respectively, with year-on-year growth rates of 20.8%, 2.0%, 13.8%, and 23.4% [3]. - Net profit attributable to shareholders is forecasted to be 238 million, 277 million, 316 million, and 388 million CNY for the same years, reflecting growth rates of 5.1%, 16.2%, 14.0%, and 22.9% [3][10]. - The price-to-earnings (PE) ratios are projected to be 44, 38, 34, and 27 for the years 2024A to 2027E [3]. R&D and Product Pipeline - The company has established a robust pipeline in the controlled narcotics sector, with recent approvals for key products such as Buprenorphine and Butorphanol, which are expected to significantly contribute to revenue growth [26][28]. - The report highlights the potential of HP-001, a leading candidate in the targeted protein degradation space, which has shown promising clinical results [9][10]. - The integration of R&D efforts between Chengdu Yuandong and Shanghai Chaoyang is anticipated to create a dual-pathway for innovation, enhancing the company's overall R&D efficiency [9][10].

Core Viewpoint - Differentiated R&D capability is one of the core competitive advantages of the company, with a focus on high-end generic drug selection and project initiation supporting early growth and capital accumulation, leading to a successful breakthrough among small and mid-cap companies [3] R&D Strategy and Integration - The company has undergone a systematic R&D strategic adjustment in 2025, integrating its existing R&D system and gaining control of Shanghai Chaoyang, which is expected to enhance its R&D capabilities significantly [4] - The integrated R&D path combines "Chengdu Yuandong's controlled substances" and "Shanghai Chaoyang's oncology/immunology," allowing the company to strengthen its existing weaknesses while steadily advancing in the controlled substances field [4] Product Pipeline and Clinical Progress - HP-001, a leading candidate in the targeted protein degradation field, shows promising clinical progress with an overall response rate (ORR) of 53% in Phase I trials, and 83% in high-dose groups [5] - HP-002, a brain-penetrating BTK PROTAC, is expected to submit an IND application in early 2026, demonstrating superior degradation efficiency compared to competitors [5] - HP-003, a VAV1 molecular glue, is anticipated to become a new star in autoimmune diseases, with plans to submit an IND in the second half of 2026 [5] - The DAC platform combines antibody precision delivery with protein-targeted degradation, showcasing the company's competitive edge in the TPD and DAC fields [5] Financial Projections - The company forecasts net profits attributable to shareholders of 277 million, 316 million, and 388 million yuan for 2025, 2026, and 2027, respectively, reflecting year-on-year growth rates of 16.2%, 14.0%, and 22.9% [6] - The current stock price corresponds to price-to-earnings (PE) ratios of 38, 34, and 27 for the respective years, with a target valuation of 15.51 billion yuan for 2026, translating to a stock price of 87.6 yuan per share [6]

成都苑东生物制药股份有限公司（以下简称"公司"）控股子公司上海超阳药 业有限公司自主研发的 1 类化学创新药 HP-001 胶囊联合地塞米松用于治疗复发 难治的多发性骨髓瘤患者 I/II 期临床试验，于近日完成首例受试者给药。现将相 关情况公告如下： 一、 HP-001 胶囊的基本情况 HP-001 胶囊是一种新型口服 CRBN（Cereblon 蛋白，E3 连接酶复合物的组 成蛋白）基础的分子胶降解剂，其作用机制为选择性招募并降解转录因子IKZF1/3， 从而激活抗肿瘤反应。临床前研究表明，HP-001 胶囊在降解效力和选择性方面 优于已获批的 IMiDs（免疫调节剂）和下一代候选药物（如 Mezigdomide、 Cemsidomide 等），对 CRBN 具有更高亲和力，能够在克服耐药机制的同时，最 大程度降低在靶及脱靶毒性。HP-001 胶囊在多发性骨髓瘤（MM）和非霍奇金 淋巴瘤（NHL）模型中展现出强大的体外和体内活性，同时安全性更高，展现出 "Best-in-Class"的潜力。 "HP-001 治疗复发难治的多发性骨髓瘤和非霍奇金淋巴瘤的 I 期临床研究" （临床试验登记号：CTR202429 ...

Core Viewpoint - The announcement highlights the initiation of a Phase I/II clinical trial for HP-001 capsules, a novel oral CRBN-based molecular degrader, in combination with dexamethasone for treating relapsed/refractory multiple myeloma patients [1] Group 1: Product Development - HP-001 capsules are a new type of oral CRBN-based molecular degrader designed to selectively recruit and degrade transcription factors IKZF1/3, thereby activating anti-tumor responses [1] - Preclinical studies indicate that HP-001 capsules demonstrate superior degradation efficacy and selectivity compared to approved IMiDs and next-generation candidates, with a higher affinity for CRBN [1] Group 2: Clinical Trial Progress - The first subject has been dosed in the clinical trial, marking a significant milestone in the development of HP-001 capsules [1] - The trial aims to evaluate the safety and efficacy of HP-001 in overcoming resistance mechanisms while minimizing on-target and off-target toxicity [1]

Group 1 - The core viewpoint of the news is that Yuan Dong Bio has experienced a significant stock price increase of 97.60% this year, despite a recent decline of 2.09% in its stock price [1] - As of December 29, the stock price is reported at 58.70 yuan per share, with a total market capitalization of 10.362 billion yuan [1] - The company has a diverse revenue structure, with 78.75% of its main business income coming from formulation sales, 9.22% from raw material sales, and smaller contributions from technology services and CMO/CDMO [1] Group 2 - As of September 30, the number of shareholders for Yuan Dong Bio has increased by 18.67% to 6,482, while the average circulating shares per person decreased by 15.74% to 27,234 shares [2] - For the period from January to September 2025, the company reported a revenue of 1.019 billion yuan, a year-on-year decrease of 2.00%, while the net profit attributable to the parent company was 220 million yuan, reflecting a year-on-year growth of 1.45% [2] - The company has distributed a total of 341 million yuan in dividends since its A-share listing, with 212 million yuan distributed over the past three years [3]

Market Overview - The A-share market experienced a broad-based rally from December 22 to December 26, with increased bullish sentiment. The Shanghai Composite Index regained the 3900-point mark, reflecting a "V-shaped" rebound despite some intraday dips, indicating a mix of year-end market dynamics and emotional fluctuations [1] Sector Highlights - The metals sector, particularly non-ferrous metals, emerged as a standout performer, frequently setting historical records. The commercial aerospace sector also showed strength, buoyed by the launch of China's first commercial aerospace social fund and the anticipated debut of new reusable rockets [1] Sichuan Stocks - Among Sichuan stocks, Xinyi Sheng led with an impressive annual gain exceeding 400%. Other notable performers included Dongcai Technology, Xinjin Road, and Development Technology, each with annual increases over 200% [2] Company Developments - Yuantong Bio's subsidiary received FDA approval for its methylene blue injection, marking the company's third successful international product launch. This approval enhances the company's international product pipeline and supports its globalization strategy [3] - Mengsheng Electronics was shortlisted in the bidding for low-orbit satellite constellation application equipment, confirming its technical capabilities. However, the specific contract details and potential revenue remain unclear [4] - Zhongyou Insurance increased its stake in Sichuan Road and Bridge to 5%, marking its fourth stake increase in listed companies this year [5][6] - Tongwei Co. established a new solar energy company, expanding its operations in solar technology and equipment sales [7] Upcoming Events - The market anticipates several key events, including a product launch by Shanjiji on December 29, which is expected to attract significant attention. Additionally, the 2025 China Green Hydrogen Industry Conference will focus on critical aspects of the green hydrogen sector [10] - The A-share market is expected to continue its upward trajectory into 2026, with a focus on technology growth and consumer recovery opportunities [11]

Macro Highlights - The Ministry of Finance, State-owned Assets Supervision and Administration Commission, Financial Regulatory Administration, and China Securities Regulatory Commission issued a notice emphasizing strict adherence to accounting standards for the preparation of 2025 annual reports, focusing on areas such as long-term equity investments, fixed assets, intangible assets, and revenue recognition [1] Industry News - In November 2025, Chinese brand passenger cars sold 2.169 million units, a month-on-month increase of 1% and a year-on-year increase of 5.8%, accounting for 71.4% of total passenger car sales, with a market share increase of 3.1 percentage points compared to the same period last year [3] - From January to November 2025, sales of Chinese brand passenger cars reached 18.978 million units, a year-on-year increase of 19.4%, representing 69.6% of total passenger car sales, with a market share increase of 4.6 percentage points compared to the same period last year [3] Company News - Kefa Electric announced that three shareholders plan to collectively reduce their holdings by 0.6999% [5] - Tongxingbao's subsidiary signed an operating contract worth 43.166 million yuan [5] - Kangchen Pharmaceutical's KC1086 project received FDA approval to commence clinical trials [5] - Yuantong Biological's methylene blue injection received drug registration approval from the US FDA [6] - Heng Rui Pharmaceutical's SHR-A1904 injection was included in the list of breakthrough therapy products [6] - Yu Huan CNC's wholly-owned subsidiary received a government subsidy of 3.565 million yuan [6] - Kangtai Biological's pentavalent vaccine has entered phase III clinical trials with the first subject enrolled [6] - Duofuduo expects its battery segment capacity to reach 50 GWh by the end of next year, planning to ship around 30 GWh [6]